中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义

段金伟 张鹏 张婧 曾婉嘉 鲁凤民

段金伟, 张鹏, 张婧, 等. 慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义[J]. 临床肝胆病杂志, 2021, 37(7): 1682-1685. DOI: 10.3969/j.issn.1001-5256.2021.07.043
引用本文: 段金伟, 张鹏, 张婧, 等. 慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义[J]. 临床肝胆病杂志, 2021, 37(7): 1682-1685. DOI: 10.3969/j.issn.1001-5256.2021.07.043
DUAN JW, ZHANG P, ZHANG J, et al. Influencing factors for serum HBsAg clearance in people with chronic hepatitis B virus infection and its clinical significance[J]. J Clin Hepatol, 2021, 37(7): 1682-1685. DOI: 10.3969/j.issn.1001-5256.2021.07.043
Citation: DUAN JW, ZHANG P, ZHANG J, et al. Influencing factors for serum HBsAg clearance in people with chronic hepatitis B virus infection and its clinical significance[J]. J Clin Hepatol, 2021, 37(7): 1682-1685. DOI: 10.3969/j.issn.1001-5256.2021.07.043

慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义

DOI: 10.3969/j.issn.1001-5256.2021.07.043
基金项目: 

艾滋病和病毒性肝炎等重大传染病防治科技重大专项课题 2017ZX10202202

艾滋病和病毒性肝炎等重大传染病防治科技重大专项课题 2017ZX10202203

详细信息
    通讯作者:

    鲁凤民,lu.fengmin@hsc.pku.edu.cn

  • 中图分类号: R512.62

Influencing factors for serum HBsAg clearance in people with chronic hepatitis B virus infection and its clinical significance

Funds: 

The National S & T Major Project for Infectious Diseases 2017ZX10202202

The National S & T Major Project for Infectious Diseases 2017ZX10202203

  • 摘要: HBsAg清除能够显著降低慢性乙型肝炎患者终末期肝病及肝癌的发病风险,但无论是自然转归还是抗病毒治疗,HBsAg的清除率都极低。经总结分析慢性HBV感染者HBsAg自发清除和抗病毒治疗清除的影响因素以及清除后的持久性等问题,并对核酸聚合物、免疫调节剂等新型在研药物的HBsAg清除潜力进行综述,以期为今后慢性乙型肝炎的临床治愈提供线索。

     

  • [1] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2] Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
    [3] ALAWAD AS, AUH S, SUAREZ D, et al. Durability of spontaneous and treatment-related loss of hepatitis B s antigen[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 700-709. e3. DOI: 10.1016/j.cgh.2019.07.018.
    [4] YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014.
    [5] YIP TC, WONG GL, WONG VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients[J]. J Hepatol, 2017. DOI: 10.1016/j.jhep.2017.09.018.[Online ahead of print]
    [6] KIM MA, KIM SU, SINN DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: A nationwide multicentre study[J]. Gut, 2020, 69(12): 2214-2222. DOI: 10.1136/gutjnl-2019-320015.
    [7] ZHOU K, CONTAG C, WHITAKER E, et al. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: A systematic review and pooled meta-analyses[J]. Lancet Gastroenterol Hepatol, 2019, 4(3): 227-238. DOI: 10.1016/S2468-1253(18)30308-X.
    [8] YEO YH, HO HJ, YANG HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and Meta-analysis[J]. Gastroenterology, 2019, 156(3): 635-646. e9. DOI: 10.1053/j.gastro.2018.10.027.
    [9] NGUYEN LH, HOANG J, NGUYEN NH, et al. Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection[J]. Aliment Pharmacol Ther, 2016, 44(4): 390-399. DOI: 10.1111/apt.13709.
    [10] OLIVERI F, SURACE L, CAVALLONE D, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance[J]. Liver Int, 2017, 37(11): 1622-1631. DOI: 10.1111/liv.13416.
    [11] SHAH PA, KAUR S, SIMONS B, et al. Patterns of HBeAg and HBsAg clearance among a treatment-naive Alaskan Cohort in a long-term observational study[J]. J Viral Hepat, 2020, 27(6): 644-646. DOI: 10.1111/jvh.13271.
    [12] ILUZ-FREUNDLICH D, SAMAD N, MILES D, et al. Spontaneous flares of chronic hepatitis B virus in hepatitis be antigen negative carriers who subsequently clear hepatitis B surface antigen[J]. Dig Dis Sci, 2021, 66(1): 257-262. DOI: 10.1007/s10620-020-06125-5.
    [13] KIM JH, LEE JH, PARK SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: A prospective follow-up study[J]. Hepatogastroenterology, 2008, 55(82-83): 578-581. http://www.ncbi.nlm.nih.gov/pubmed/18613411/
    [14] CHU CM, LIAW YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up[J]. Hepatology, 2007, 45(5): 1187-1192. DOI: 10.1002/hep.21612.
    [15] CHEN YC, CHU CM, YEH CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: A long-term follow-up study[J]. Hepatol Int, 2007, 1(1): 267-273. DOI: 10.1007/s12072-007-5001-0.
    [16] LIU F, WANG XW, CHEN L, et al. Systematic review with meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance[J]. Aliment Pharmacol Ther, 2016, 43(12): 1253-1261. DOI: 10.1111/apt.13634.
    [17] LIAW YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 631-641. DOI: 10.1038/s41575-019-0197-8.
    [18] LIU J, LI T, ZHANG L, et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: A systematic review[J]. Hepatology, 2019, 70(3): 1045-1055. DOI: 10.1002/hep.30474.
    [19] LIMOTHAI U, CHUAYPEN N, POOVORAWAN K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(12): 1481-1488. DOI: 10.1111/jvh.13195.
    [20] YAN Y, ALLWEISS L, YANG D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8(1): 879-894. DOI: 10.1080/22221751.2019.1625728.
    [21] CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066. DOI: 10.1002/hep.29213.
    [22] WONG D, LITTLEJOHN M, EDWARDS R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B[J]. Liver Int, 2018, 38(10): 1760-1769. DOI: 10.1111/liv.13716.
    [23] BERG T, SIMON KG, MAUSS S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study[J]. J Hepatol, 2017, 67(5): 918-924. DOI: 10.1016/j.jhep.2017.07.012.
    [24] LIAW YF. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: To retreat or not to retreat[J]. Hepatology, 2021, 73(2): 843-852. DOI: 10.1002/hep.31525.
    [25] PEPPA D, GILL US, REYNOLDS G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J]. J Exp Med, 2013, 210(1): 99-114. DOI: 10.1084/jem.20121172.
    [26] DONG Y, CHEN H, GAO J, et al. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease[J]. J Mol Cell Cardiol, 2019, 136: 27-41. DOI: 10.1016/j.yjmcc.2019.09.001.
    [27] WANG H, LUO H, WAN X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56. DOI: 10.1016/j.jhep.2019.08.024.
    [28] LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
    [29] OLIVIERO B, CERINO A, VARCHETTA S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections[J]. J Hepatol, 2011, 55(1): 53-60. DOI: 10.1016/j.jhep.2010.10.016.
    [30] ZIMMER CL, RINKER F, HÖNER ZU SIEDERDISSEN C, et al. Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss[J]. J Infect Dis, 2018, 217(10): 1656-1666. DOI: 10.1093/infdis/jiy097.
    [31] PEPPA D, GILL US, REYNOLDS G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J]. J Exp Med, 2013, 210(1): 99-114. DOI: 10.1084/jem.20121172.
    [32] LI H, ZHAI N, WANG Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044. DOI: 10.1136/gutjnl-2017-314098.
    [33] MICHLER T, KOSINSKA AD, FESTAG J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice[J]. Gastroenterology, 2020, 158(6): 1762-1775. e9. DOI: 10.1053/j.gastro.2020.01.032.
    [34] NING Q, WU D, WANG GQ, et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus[J]. J Viral Hepat, 2019, 26(10): 1146-1155. DOI: 10.1111/jvh.13126.
    [35] LIU J, WANG T, ZHANG W, et al. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: A systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(6): 958-972. DOI: 10.1007/s12072-020-10099-x.
    [36] VAILLANT A. REP 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection[J]. ACS Infect Dis, 2019, 5(5): 675-687. DOI: 10.1021/acsinfecdis.8b00156.
    [37] BAZINET M, PÂNTEA V, PLACINTA G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158(8): 2180-2194. DOI: 10.1053/j.gastro.2020.02.058.
    [38] YUEN MF, GANE E, KIM DJ, et al. AS069-RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy[J]. J Hepatol, 2020, 73(Suppl 1): s51. DOI: 10.1016/S0168-8278(20)30648-6.
    [39] GANE E, LOCARNINI S, LIM TH, et al. GS10-Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment[J]. J Hepatol, 2020, 73(Suppl 1): s20. DOI: 10.1016/S0168-8278(20)30597-3.
    [40] GUPTA SV, FANGET MC, BAKARDJIEV A, et al. SAT462-Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers[J]. J Hepatol, 2020, 73(Suppl 1): s885. DOI: 10.1016/S0168-8278(20)32207-8.
    [41] CHEN D, KIM S, BROOKS A, et al. FRI350-Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod[J]. J Hepatol, 2020, 73(Suppl 1): s571-s572. DOI: 10.1016/S0168-8278(20)31616-0.
    [42] HAGUE RM, HINE D, FERGUSSON J, et al. SAT458 - Immtav, a novel immunotherapy approach to eliminate hepatitis B virus[J]. J Hepatol, 2020, 73(Suppl 1): s882. 10.1016/S0168-8278(20)32203-0. http://www.sciencedirect.com/science/article/pii/S0168827820322030
    [43] WU Y, LIU Y, LU J, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 514-516. e2. DOI: 10.1016/j.cgh.2019.04.020.
    [44] LI MH, YI W, ZHANG L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26(Suppl 1): 32-41. DOI: 10.1111/jvh.13151.
    [45] WU Y, WANG X, LIN X, et al. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance[J]. J Microbiol Immunol Infect, 2021, 54(2): 238-244. DOI: 10.1016/j.jmii.2019.09.004.
    [46] LU FM, WANG J, CHEN XM, et al. The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J]. J Chin Hepatol, 2017, 25(2): 105-110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005.

    鲁凤民, 王杰, 陈香梅, 等. 乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J]. 中华肝脏病杂志, 2017, 25(2): 105-110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005.
  • 加载中
计量
  • 文章访问数:  181
  • HTML全文浏览量:  48
  • PDF下载量:  67
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-05
  • 修回日期:  2021-01-25
  • 刊出日期:  2021-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回